Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The researchers also assessed the effect on acute inflammatory response to inhaled LPS challenge following γT treatment, focusing on changes in sputum neutrophilia, mucins, and cytokines.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

Mucociliary clearance was measured using gamma scintigraphy.

What Was Measured

PubMed files the paper under topics including Asthma, Biomarkers, Endotoxins, Eosinophilia, Eosinophils, Mucins and Neutrophil Infiltration.

Author keywords: lipopolysaccharide, mucociliary clearance, tocopherol and vitamin E.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (The Journal of allergy and clinical immunology), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.